These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26879084)

  • 1. Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.
    Gzell CE; Wheeler HR; McCloud P; Kastelan M; Back M
    J Neurooncol; 2016 May; 128(1):67-74. PubMed ID: 26879084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
    Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
    Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
    Ellingson BM; Wen PY; Cloughesy TF
    Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
    Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
    Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
    Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma survival is better analyzed on preradiotherapy MRI than on postoperative MRI residual volumes: A retrospective observational study.
    De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Charni S; Cohen-Jonathan-Moyal E; Roux FE
    Clin Neurol Neurosurg; 2020 Sep; 196():105972. PubMed ID: 32512407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earliest radiological progression in glioblastoma by multidisciplinary consensus review.
    Eijgelaar RS; Bruynzeel AME; Lagerwaard FJ; Müller DMJ; Teunissen FR; Barkhof F; van Herk M; De Witt Hamer PC; Witte MG
    J Neurooncol; 2018 Sep; 139(3):591-598. PubMed ID: 29777418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
    Müller A; Jurcoane A; Kebir S; Ditter P; Schrader F; Herrlinger U; Tzaridis T; Mädler B; Schild HH; Glas M; Hattingen E
    Cancer Med; 2017 Jan; 6(1):89-99. PubMed ID: 27891815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quantitative study of shape descriptors from glioblastoma multiforme phenotypes for predicting survival outcome.
    Chaddad A; Desrosiers C; Hassan L; Tanougast C
    Br J Radiol; 2016 Dec; 89(1068):20160575. PubMed ID: 27781499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
    Melguizo-Gavilanes I; Bruner JM; Guha-Thakurta N; Hess KR; Puduvalli VK
    J Neurooncol; 2015 May; 123(1):141-50. PubMed ID: 25894594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
    Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
    Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining pseudoprogression in glioblastoma multiforme.
    Van Mieghem E; Wozniak A; Geussens Y; Menten J; De Vleeschouwer S; Van Calenbergh F; Sciot R; Van Gool S; Bechter OE; Demaerel P; Wilms G; Clement PM
    Eur J Neurol; 2013 Oct; 20(10):1335-41. PubMed ID: 23679051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.